Guidant's Guiding Spirit: An Interview with Beverly Lorell, MD
Executive Summary
Like all medical device companies, Guidant is facing a world of unprecedented changes, most notably the emergence of drug/device therapies that will require radically different skill sets and development strategies. To help it cope with the challenges and opportunities to come, Guidant reached into the academic cardiology community, appointing an internationally-recognized expert in interventional cardiology and heart failure, Beverly Lorell, to oversee the future of its device technology. Lorell will be no ivory-tower academic. She'll help Guidant understand the clinical issues while working through the related business issues, including the growing complexity of the clinical trials process and the proper influence that marketing and sales imperatives should play on product development.
You may also be interested in...
How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook
Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.
X-Cell Medical: Putting Safety First
Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.
X-Cell Medical: Putting Safety First
Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.